TA 5493

Drug Profile

TA 5493

Alternative Names: TA-5493

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Antipsoriatics; Antirheumatics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 27 May 2010 TA 5493 is still in phase I trials for Rheumatoid arthritis and psoriasis in the EU
  • 01 Oct 2007 Tanabe Seiyaku Co. Ltd has merged with Mitsubishi Pharma Corporation to form Mitsubishi Tanabe Pharma Corporation
  • 28 Aug 2006 Phase-I clinical trials in Psoriasis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top